ReviewPrecision radiation oncology2024
Current status and prospect of particle therapy for esophageal cancer.
Review in Precision radiation oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Association of preoperative controlling nutritional status score with clinical outcomes among surgical patients with esophageal cancer: a meta-analysis.Frontiers in oncology · 2025Pooled it
- Radiation dose and pathological complete response rate of neoadjuvant chemoradiotherapy for esophageal squamous cell carcinoma: a model-based dose-response meta-analysis.Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al] · 2026Article
- Targeted tumor starvation strategy augments radiosensitivity and enhances radioactive iodine-mediated tumor immunotherapy.Acta pharmacologica Sinica · 2026Article
- Activation of NF-κB signaling pathway in GSDME-low esophageal squamous cell carcinoma cells enhances radioresistance.Journal of translational medicine · 2026Article
- Esophageal cancer staging in Malawi: the feasibility of chest radiography and abdominal ultrasound for initial evaluation.BMC gastroenterology · 2025Observational
- Development and validation of NTCP models for predicting acute esophagitis in carbon ion radiotherapy for thoracic malignancies.BMC cancer · 2025Article
- Automated segmentation of esophageal squamous cell carcinoma in contrast-enhanced free-breathing 3D-GRE: a comparative study of UNet, nnUNet, and UMamba for tumor delineation.BMC medical imaging · 2025Article
- Preoperative esophageal cancer staging assessment based on intravoxel incoherent motion and apparent diffusion coefficient: a comparative study of maximum-diameter slice region of interest and whole volume of interest analysis.BMC medical imaging · 2025Article
- Assessment of intra-fractional and inter-fractional motion in esophageal cancer treated with intensity-modulated proton therapy.BMC cancer · 2025Article
- Prognostic impact of CT-derived muscle-adipose index change in patients with inoperable esophageal squamous cell carcinoma undergoing chemoradiotherapy.Frontiers in oncology · 2025Article
- Clinicopathologic features of superficial esophageal squamous cell carcinoma in different infiltrative growth pattern.Frontiers in oncology · 2025Article
- Construction and validation of a necroptosis-related lncRNA signature for predicting the prognosis of gastrointestinal cancer patients.Frontiers in immunology · 2025Article
- Current status and prospect of particle therapy for esophageal cancer.Precision radiation oncology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Esophageal cancer is among the top causes of cancer-related mortality worldwide, and the main treatment modality for locally advanced esophageal cancer is concurrent chemoradiotherapy. The current photon-based radiotherapy modalities and procedures have increased the incidence of treatment-related cardiac and pulmonary complications. Additionally, anatomical changes in the esophagus resulting from diaphragmatic movement, weight loss, and tumor progression present challenges for radiotherapy. These challenges have spurred interest in particle therapies, such as proton beam therapy (PBT) and heavy-ion therapy, for esophageal cancer. This paper comprehensively reviews the dosimetric advantages, clinical efficacy, and limitations of PBT and heavy-ion therapy for esophageal cancer and discusses their prospects. This highlights the unique dosimetric benefits of these therapies, particularly their ability to deliver high-dose radiation precisely to the tumor while sparing the surrounding normal organs and tissues. Although PBT and heavy-ion therapy demonstrate superior clinical efficacy compared to photon therapy, they are not without limitations. Multiple studies are needed to further validate and supplement the existing clinical and preclinical data to better exploit the benefits of PBT and thereby provide improved survival advantages to these patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.